Citations

Clear

163 citation(s) found for "Sharp, H L".

A National Survey of Transplant Surgeons and Nephrologists on Implementing Apolipoprotein L1 ( APOL1 ) Genetic Testing Into Clinical Practice
Gordon, Elisa J. , Wicklund, Catherine , Lee, Jungwha , Sharp, Richard R. , Sharp, Richard R , Friedewald, John J.

Mayo Clinic

Progress in Transplantation | December 13, 2018 | Volume: 29 | Issue: 1 | Pages: 26-35

10.1177/1526924818817048 | PMID 30541404 Get It

Introduction: There is debate over whether Apolipoprotein L1 (APOL1) gene risk variants contribute to African American (AA) live donors’ (LD) increased risk of kidney failure. Little is known about factors influencing physicians’ integration of APOL1 genetic testing of AA LDs into donor evaluation. Design: We conducted a cross-sectional survey, informed by Roger’s Diffusion of Innovations theory, among nephrology and surgeon members of the American Society of Nephrology, American Society of Transplantation, and American Society of Transplant Surgeons about their practices of and attitudes about APOL1 genetic testing of AA potential LDs. Descriptive statistics and bivariate analyses were performed. Results: Of 383 completed surveys, most physicians believed that APOL1 testing can help AA LDs make more informed donation decisions (87%), and the addition of APOL1 testing offers better clinical information about AA LD’s eligibility for donation than existing evaluation approaches (74%). Among respondents who evaluate LDs (n = 345), 63% would definitely or probably begin or continue using APOL1 testing in the next year, however, few use APOL1 testing routinely (4%) or on a case-by-case basis (14%). Most did not know the right clinical scenario to order APOL1 testing (59%), but would use educational materials to counsel AA LDs about APOL1 testing (97%). Discussion: Although physicians were highly supportive of APOL1 genetic testing for AA LDs, few physicians use APOL1 testing. As more physicians intend to use APOL1 testing, an ethical framework and clinical decision support are needed presently to assist clinicians in clarifying the proper indication of APOL1 genetic testing.
Dose expansion cohort of a phase I trial of M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC).
Plummer, Elizabeth Ruth, Cook, Natalie , Melear, Jason M., Redfern, Charles H., Chung, Ki Y. , Haddad, Tufia C. , Goddemeier, Thomas, Arkenau, Hendrik‐Tobias , Spira, Alexander I. , Shapiro, Geoffrey I. , Ramalingam, Suresh S. , Wesolowski, Robert , Falk, Martin H., Dean, Emma

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e21048-e21048

10.1200/jco.2018.36.15_suppl.e21048 Get It

Pump Position Impacts HeartMate II Left Ventricular Assist Device Thrombosis
Ransom, John , Maltais, Simon, Sun, Benjamin , Entwistle, John W. , Bailey, Stephen, John, Ranjit , Klodell, C.T., Gregorič, Igor D. , Sheridan, Brett C. , Chuang, Joyce, Farrar, David J. , Sundareswaran, Kartik S., Adamson, Robert, Kılıç, Ahmet

Mayo Clinic

ASAIO Journal | June 26, 2018 | Volume: 65 | Issue: 3 | Pages: 227-232

10.1097/mat.0000000000000840 | PMID 29952801 Get It

The PREVENtion of HeartMate II pump Thrombosis through clinical management (PREVENT) study was a multicenter, prospective investigation to evaluate the rate of pump thrombosis (PT) with adoption of a uniform set of surgical and medical practices for left ventricular assist device implantation. We sought to quantify pump position at baseline and retrospectively define a pump position associated with poor clinical outcomes. Chest x-rays at baseline were prospectively obtained per protocol. Pump pocket depth, inflow cannula (IC) angle relative to the pump, and IC angle relative to the vertical were measured. Pumps falling in the tail-ends of the IC angle and pump pocket depth distributions were categorized as having an extreme pump position within the PREVENT study. Patients with extreme pump position had a significantly higher risk of confirmed and suspected PT, hemolysis, and elevated lactate dehydrogenase. In a multivariable analysis of survival free of confirmed PT, extreme pump position was an independent risk factor (hazard ratio = 3.6; 95% confidence interval = 1.5–8.9; p = 0.006) when adjusting for differences in pump speed and anticoagulation level. Our analysis shows that HeartMate II pump position at implant can significantly impact event-free survival and the incidence of adverse events at 6 months.
When to Avoid Giving Advice on the Ethical Conduct of Research
Sharp, Richard R. , Allyse, Megan , Allyse, Megan A., Sharp, Richard R , Allyse, Megan A

Mayo Clinic

The American Journal of Bioethics | April 6, 2018 | Volume: 18 | Issue: 4 | Pages: 94-95

10.1080/15265161.2018.1431721 | PMID 29621454 Get It

TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficien
Ryan, Charles J. , Abida, Wassim , Dumbadze, Igor, Given, Robert , Petrylak, Daniel P. , Redfern, Charles H., Scher, Howard I. , Watkins, Simon P. , Simmons, Andrew D. , Passler, Luke, Golsorkhi, Tony, Chowdhury, Simon, Watkins, Simon P , Bryce, Alan H. , Balar, Arjun Vasant , Morris, David S. , Passler, Luke

Mayo Clinic

Journal of Clinical Oncology | February 26, 2018 | Volume: 36 | Issue: 6_suppl | Pages: TPS389-TPS389

10.1200/jco.2018.36.6_suppl.tps389 Get It

TPS389 Background: Recent data have shown that up to 25% of patients with advanced prostate cancer, including mCRPC, have a deleterious germline or somatic mutation in BRCA1, BRCA2, ATM, or another homologous recombination DNA repair gene. Such mutations can be used as a molecular marker to select patients for targeted treatment with poly(ADP-ribose) polymerase inhibitors (PARPis), which are lethal to cells with HRD. Treatment with PARPis has shown preliminary evidence of antitumor activity in patients with mCRPC and a mutation in a homologous recombination DNA repair gene (Mateo et al. N Engl J Med. 2015;373:1697-708). These data provide a compelling rationale for evaluating rucaparib, a potent inhibitor of PARP1, PARP2, and PARP3, in patients with mCRPC associated with HRD. Methods: TRITON3 (NCT02975934) is a randomized, phase 3 study evaluating rucaparib 600 mg BID vs physician’s choice of abiraterone, enzalutamide, or docetaxel in patients with mCRPC and a deleterious germline or somatic BRCA1, BRCA2, or ATM mutation (identified by prior local testing or central testing during screening). Patients must have progressed on androgen receptor signaling–directed therapy in the mCRPC setting; prior PARPi treatment or chemotherapy for mCRPC are exclusion criteria. Patients will be randomly assigned in a 2:1 ratio to either rucaparib or physician’s choice, with the possibility for cross over from the comparator treatment to rucaparib upon radiographic progression confirmed by independent radiology review. The primary endpoint is radiographic progression-free survival (modified RECIST v1.1/PCWG3 criteria) assessed by independent radiology review. Secondary endpoints include objective response rate, duration of response, patient-reported outcomes, overall survival, and safety. Pretreatment blood samples collected from all patients will enable development of a noninvasive plasma-based companion diagnostic to select patients who may benefit from rucaparib treatment. Patients (≈400) will be enrolled at > 100 sites worldwide. Clinical trial information: NCT02975934.
Ethical Considerations Related to Return of Results from Genomic Medicine Projects: The eMERGE Network (Phase III) Experience
Fossey, Robyn, Kochan, David C., Winkler, Erin, Pacyna, Joel E. , Thibodeau, Stephen N. , Connolly, John J. , Harr, Margaret , Behr, Meckenzie, Prows, Cynthia A. , Cobb, Beth L., Myers, Melanie F. , Leslie, Nancy, Namjou‐Khales, Bahram, Rasouly, Hila Milo , Wynn, Julia , Fedotov, Alexander , Gharavi, Ali G. , Williams, Janet L. , Pais, Lynn , Holm, Ingrid A. , Aufox, Sharon , Smith, Maureen E. , Scrol, Aaron, Leppig, Kathleen A. , Jarvik, Gail P. , Wiesner, Georgia L. , Li, Rongling, Stroud, Mary , Sharp, Richard R. , Kochan, David, Thibodeau, Stephen, Myers, Melanie F , Holm, Ingrid A , Sharp, Richard R , Milo Rasouly, Hila , Jarvik, Gail P , Connolly, John J , Olson, Janet E. , Chung, Wendy K. , Smoller, Jordan W. , Kullo, Iftikhar J.

Mayo Clinic

Journal of Personalized Medicine | January 3, 2018 | Volume: 8 | Issue: 1 | Pages: 2

10.3390/jpm8010002 | PMID 29301385 Get It

We examined the Institutional Review Board (IRB) process at 9 academic institutions in the electronic Medical Records and Genomics (eMERGE) Network, for proposed electronic health record-based genomic medicine studies, to identify common questions and concerns. Sequencing of 109 disease related genes and genotyping of 14 actionable variants is being performed in ~28,100 participants from the 9 sites. Pathogenic/likely pathogenic variants in actionable genes are being returned to study participants. We examined each site’s research protocols, informed-consent materials, and interactions with IRB staff. Research staff at each site completed questionnaires regarding their IRB interactions. The time to prepare protocols for IRB submission, number of revisions and time to approval ranged from 10–261 days, 0–11, and 11–90 days, respectively. IRB recommendations related to the readability of informed consent materials, specifying the full range of potential risks, providing options for receiving limited results or withdrawal, sharing of information with family members, and establishing the mechanisms to answer participant questions. IRBs reviewing studies that involve the return of results from genomic sequencing have a diverse array of concerns, and anticipating these concerns can help investigators to more effectively engage IRBs.
Modernizing Research Regulations Is Not Enough: It's Time to Think Outside the Regulatory Box
Rivera, Suzanne M. , Brothers, Kyle B. , Cadigan, R. Jean , Harrell, Heather L., Rothstein, Mark A., Sharp, Richard R. , Goldenberg, Aaron J. , Sharp, Richard R

Mayo Clinic

The American Journal of Bioethics | June 29, 2017 | Volume: 17 | Issue: 7 | Pages: 1-3

10.1080/15265161.2017.1328899 | PMID 28661748 Get It

Consumer Perspectives on Access to Direct‐to‐Consumer Genetic Testing: Role of Demographic Factors and the Testing Experience
Gollust, Sarah E. , Gray, Stacy W. , Carere, Deanna Alexis , Koenig, Barbara A. , McGuire, Amy , Sharp, Richard R. , Spector‐Bagdady, Kayte , Wang, Na , Roberts, J. Scott , Group, for the PGen Study, Roberts, J. Scott , Lehmann, Lisa Soleymani , Green, Robert C. , Group, for the PGen Study, Sharp, Richard R , Gray, Stacy W

Mayo Clinic

The Milbank Quarterly | June 7, 2017 | Volume: 95 | Issue: 2 | Pages: 291-318

10.1111/1468-0009.12262 | PMID 28589610 Get It

Policy Points: The policy context of direct‐to‐consumer personal genomic testing (DTC‐PGT) has been evolving over the last decade, with little empirical data available about consumers’ perspectives. A majority of consumers of DTC‐PGT supported expanded access to services and their integration into the medical context and opposed more governmental regulation. Consumers’ attitudes about access to services and regulation did not vary based on the specific genetic risk information they received from companies, but may vary based on whether consumers perceived their DTC experience negatively. ContextWhile policymakers have been considering the appropriateness of direct‐to‐consumer personal genomic testing (DTC‐PGT) for more than a decade, there is little empirical data on consumers’ views regarding the regulation of these products. No research has assessed whether consumers’ personal experience with testing is related to their views about access to and regulation of DTC tests.MethodsData were analyzed from the PGen Study, a longitudinal prospective cohort of DTC‐PGT customers of 23andMe (n = 564) and Pathway Genomics (n = 377; total N = 941). Consumers were sent an electronic survey before receiving genetic test results and again 6 months after receipt of results.FindingsAt the 6‐month follow‐up, more than 80% of participants believed that people have a right to access genetic information directly, that parents should be able to get DTC‐PGT testing for their children, and that genetic information should be kept private. Participants supported health insurance coverage of PGT (60%), wider availability of PGT (68%), and inclusion of genetic information in medical records (63%). Participants were less supportive of government regulation (28%) and restricting testing to clinical settings (14%). Conservative political ideology was associated with less support for government regulation (P < 0.001), as was feeling more confident in one's genetic knowledge (P < 0.05). Participants’ level of computed genetic risk for common diseases, as indicated by their actual test results received from companies, showed no relationship with attitudes. However, those who perceived that they had received elevated risk results expressed lower support for expanded availability and incorporation of PGT into health care (P < 0.01). Those who reported being upset by their genetic test results were less likely to endorse access to DTC products without a medical professional (P < 0.01).ConclusionsPGT consumers supported expanded access to these services and opposed additional regulation. Users who had a negative personal experience with PGT testing were less supportive of expanded availability without a medical professional.